Cimit News
Funding Opportunity: Blueprint Medtech Winter Award Competition
    
CIMIT’s CINTA and NeuroTech Harbor, through the NIH Blueprint MedTech program, are accepting pre-proposals from academic and industry applicants who have emerging preventative, therapeutic, or diagnostic medical devices focused on disorders of the nervous system. 
Awards up to $500K will be made available to the most promising and innovative neurotechnologies to help accelerate their development toward commercialization. 
A major emphasis of this program is to create opportunities for diverse innovators, including those who have been traditionally underrepresented in the neurotech space. 
Award Types 
Optimizer Awards: 
	- Up to $500,000 in direct costs per year for up to 4 years. 
 
	- Ongoing mentorship from experienced executives. 
 
	- Comprehensive resources and support services. 
 
Seedling Awards: 
	- 6-months of support. 
 
	- A $25,000 stipend. 
 
	- An additional $25,000 to hire subject matter experts. 
 
	- Ongoing mentorship to overcome identified gaps. 
	  
The deadline for this opportunity has passed.
    
CIMIT’s CINTA and NeuroTech Harbor, through the NIH Blueprint MedTech program, are accepting pre-proposals from academic and industry applicants who have emerging preventative, therapeutic, or diagnostic medical devices focused on disorders of the nervous system.
Awards up to $500K will be made available to the most promising and innovative neurotechnologies to help accelerate their development toward commercialization.
A major emphasis of this program is to create opportunities for diverse innovators, including those who have been traditionally underrepresented in the neurotech space.
Award Types
Optimizer Awards:
- Up to $500,000 in direct costs per year for up to 4 years.
 - Ongoing mentorship from experienced executives.
 - Comprehensive resources and support services.
 
Seedling Awards:
- 6-months of support.
 - A $25,000 stipend.
 - An additional $25,000 to hire subject matter experts.
 - Ongoing mentorship to overcome identified gaps. 
 
The deadline for this opportunity has passed.